摘要
目的研究肿瘤坏死因子和N-CWS介入性治疗中晚期肝癌的临床与二步切除。方法232例中晚期肝癌随机分为免疫化疗栓塞组(治疗组)80例,化疗栓塞组(对照组)152例,二组病期相似,均行肝动脉化疗栓塞,注入相向化疗方案和剂量(5-氟尿嘧啶、顺铂和阿霉素或丝裂霉素),用碘化油和明胶海棉为栓塞剂。治疗组同时配合肿瘤坏死因子和N-CWS免疫治疗。结果治疗组13例(16.2%)、对照组19例(12.5%)行二步切除术,治疗组的肿瘤缩小率和二步切除率均比对照组高,治后1年、2年和3年生存率分别比对照组提高9.3%,8.6%和11.0%(P>0.05)。免疫功能治疗组下降不明显(P>0.05),而对照组明显下降(P<0.05)。结论肿瘤坏死因子和N-CWS介入性治疗能提高患者的免疫功能,延长生存期,具有广泛的应用前景。
To study the use of TNF and NCWS combinded with two-stage resection of moderate or advanced hepatic carcinoma.Methods 232 patients withmoderate or advanced stage of hepatic carcinoma were treated in our hospital.80 cases were randomly distributed into immuno-chemo-embolization group and another 152 cases into chemo-embolization group(control).There was no apparent difference of clinical stage between the two groups.These two groups were received the same chemo-therapeutical regime plus embolization.Tumour necrosis factor(TNF)500 kU and nocardia rubra cell wall skeleton(N-CWS)400μg were given as an immuno-therapeutical agent at the same time in the therapeutical group.13 patients(16.2%)were undergone two-stage resection in therapeutical group.Whereas 19 patients(12.5%)undergone resection in control group.Results(1)Tumour shrinkage rate and two-stage resection rate in therapeutical group were higher than those in control group.(2)In therapeutical group,1-year,2-year and 3-year survival rate were increased up to 9.3%,8.6% and 11.0% respectively from those of control group but these was no significant difference between these two groups(P>0.05).(3)The patients immunofunctions were not markedly decreased in therapeutical group.However,immunofunctions were considerably decreased in control group after treatment(P<0.05).Conclusion TNF and N-CWS are capable of enhancing patients systemic immunofunction of patients during treatment for moderate or advanced hepatic cancer.
基金
福建省计委"八.五"重点攻关课题
关键词
肝肿瘤
肿瘤坏死因子
红色诺卡氏菌
细胞壁骨架
primary liver cancer tumour necrosis factor nocardia rubra cell wall skeleton